Acute and conditioned sickness reduces morphine analgesia

Behavioural Brain Research

Volumn 142, Issue 1-2, 2003, Pages 89-97

  Johnston, Ian N ^a   Westbrook, R Frederick ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Analgesia; Antianalgesia; Conditioned illness; Illness; Lipopolysaccharides; Lithium chloride; Morphine; Tolerance

Indexed keywords

ANALGESIC AGENT; LIPOPOLYSACCHARIDE; LITHIUM CHLORIDE; MORPHINE; OPIATE RECEPTOR; TOXIN;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DESENSITIZATION; DRUG TOLERANCE; GENERAL ASPECTS OF DISEASE; HYPERALGESIA; MALE; NERVE CELL NETWORK; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

EID: 0037602115     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(02)00398-4     Document Type: Article

References (83)

1. Apfel S.C., Newel M., Dormia C., Kessler J.A. Kappa opioid receptors participate in nerve growth factor-induced hyperalgesia. Neuroscience. 68:1995;1199-1206.
2. Baker T.B., Tiffany S.T. Morphine tolerance as habituation. Psychol. Rev. 92:1985;78-108.
3. Baumann H., Gauldie J. The acute phase response. Immunol. Today. 15:1994;74-80.
4. Bederson J.B., Fields H.L., Barbaro N.M. Hyperalgesia during naloxone-precipitated withdrawal from morphine is associated with increased on-cell activity in the rostral ventromedial medulla. Somatosens. Mot. Res. 7:1990;185-203.
5. Bespalov A.Y., Zvartau E.E., Beardsley P.M. Opioid-NMDA receptor interactions may clarify conditioned (associative) components of opioid analgesic tolerance. Neurosci. Biobehav. Rev. 25:2001;343-353.
6. Bhargava H.N., Zhao G.M. Effect of nitric oxide synthase inhibition on tolerance to the analgesic action of D-Pen2, D-Pen5 enkephalin and morphine in the mouse. Neuropeptides. 30:1996;219-223.
7. Blalock J.E. A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol. Rev. 69:1989;1-32.
8. Blatteis C.M., Xin L., Quan N. Neuromodulation of fever: apparent involvement of opioids. Brain Res. Bull. 26:1991;219-223.
9. Brouckaert P., Libert C., Everaerdt B., Takahashi N., Cauwels A., Fiers W. Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. Immunobiology. 187:1993;317-329.
10. Burns G., Herz A., Nikolarakis K.E. Stimulation of hypothalamic opioid peptide release by lithium is mediated by opioid autoreceptors: evidence from a combined in vitro, ex vivo study. Neuroscience. 36:1990;691-697.
11. Celerier E., Laulin J., Larcher A., Le Moal M., Simonnet G. Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res. 847:1999;18-25.
12. Celerier E., Laulin J.P., Corcuff J.B., Le Moal M., Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J. Neurosci. 21:2001;4074-4080.
13. Chang R.C., Rota C., Glover R.E., Mason R.P., Hong J.S. A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy. Brain Res. 854:2000;224-229.
14. Coelho A., Fioramonti J., Bueno L. Brain interleukin-1beta and tumor necrosis factor-alpha are involved in lipopolysaccharide-induced delayed rectal allodynia in awake rats. Brain Res. Bull. 52:2000;223-228.
15. Coelho A.M., Fioramonti J., Bueno L. Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines, and vagus nerve. Am. J. Physiol. Gastrointest. Liver Physiol. 279:2000;G781-G790.
16. Coudore-Civiale M.A., Courteix C., Fialip J., Boucher M., Eschalier A. Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats. Pain. 88:2000;15-22.
17. Crain S.M., Shen K.F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 84:2000;121-131.
18. Crain S.M., Shen K.F. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res. 888:2001;75-82.
19. Das K.P., McMillian M.K., Bing G., Hong J.S. Modulatory effects of [Met5]-enkephalin on interleukin-1 beta secretion from microglia in mixed brain cell cultures. J. Neuroimmunol. 62:1995;9-17.
20. de Gandarias J.M., Acebes I., Echevarria E., Vegas L., Abecia L.C., Casis L. Lithium alters mu-opioid receptor expression in the rat brain. Neurosci. Lett. 279:2000;9-12.
21. Dunbar S.A., Pulai I.J. Repetitive opioid abstinence causes progressive hyperalgesia sensitive to N-methyl-D-aspartate receptor blockade in the rat. J. Pharmacol. Exp. Ther. 284:1998;678-686.
22. Elliott K., Minami N., Kolesnikov Y.A., Pasternak G.W., Inturrisi C.E. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 56:1994;69-75.
23. Fontela T., Garcia Hermida O., Gomez-Acebo J. Blocking effect of naloxone, dihydroergotamine and adrenalectomy in lithium-induced hyperglycaemia and glucose intolerance in the rat. Acta Endocrinol. 111:1986;342-348.
24. Hart B.L. Biological basis of the behavior of sick animals. Neurosci. Biobehav. Rev. 12:1988;123-137.
25. Hawranko A.A., Serafini M., Smith D.J. Anti-analgesia and reduced antinociception from supraspinally administered beta-endorphin in stressed rats: dependence on spinal cholecystokinin via cholecystokinin B receptors. Neurosci. Lett. 267:1999;101-104.
26. Holmes B.B., Rady J.J., Smith D.J., Fujimoto J.M. Supraspinal neurotensin-induced antianalgesia in mice is mediated by spinal cholecystokinin. Jpn. J. Pharmacol. 79:1999;141-149.
27. Kayser V., Besson J.M., Guilbaud G. Further evidence for a bidirectional effect of naloxone on the pain threshold in tolerant and non-tolerant arthritic rats. Neuropeptides. 5:1984;49-52.
28. Kim J.A., Siegel S. The role of cholecystokinin in conditional compensatory responding and morphine tolerance in rats. Behav. Neurosci. 115:2001;704-709.
29. Larson S.J., Dunn A.J. Behavioral effects of cytokines. Brain Behav. Immun. 15:2001;371-387.
30. Laulin J.P., Celerier E., Larcher A., Le Moal M., Simonnet G. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience. 89:1999;631-636.
31. Lauretti G.R., Lima I.C., Reis M.P., Prado W.A., Pereira N.L. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology. 90:1999;1528-1533.
32. Lenox R.H., McNamara R.K., Papke R.L., Manji H.K. Neurobiology of lithium: an update. J. Clin. Psychiatry. 59:1998;37-47.
33. Li X., Angst M.S., Clark J.D. A murine model of opioid-induced hyperalgesia. Brain research. Mol. Brain Res. 86:2001;56-62.
34. Lieblich I., Yirmiya R. Naltrexone reverses a long term depressive effect of a toxic lithium injection on saccharin preference. Physiol. Behav. 39:1987;547-550.
35. Lysle D.T., How T. Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes. J. Pharmacol. Exp. Ther. 288:1999;502-508.
36. Ma W., Zheng W.H., Kar S., Quirion R. Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons. Neuroscience. 99:2000;529-539.
37. Maier S.F., Watkins L.R. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol. Rev. 105:1998;83-107.
38. Maier S.F., Wiertelak E.P., Martin D., Watkins L.R. Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res. 623:1993;321-324.
39. Mao J., Price D.D., Mayer D.J. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain. 61:1995;353-364.
40. McCarthy L., Wetzel M., Sliker J.K., Eisenstein T.K., Rogers T.J. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 62:2001;111-123.
41. McNally G.P. Pain facilitatory circuits in the mammalian central nervous system: their behavioral significance and role in morphine analgesic tolerance. Neurosci. Biobehav. Rev. 23:1999;1059-1078.
42. McNally G.P., Johnston I.N., Westbrook R.F. A peripheral, intracerebral, or intrathecal administration of an opioid receptor antagonist blocks illness-induced hyperalgesia in the rat. Behav. Neurosci. 114:2000;1183-1190.
43. McNally G.P., Westbrook R.F. Effects of systemic, intracerebral, or intrathecal administration of an N-methyl-D-aspartate receptor antagonist on associative morphine analgesic tolerance and hyperalgesia in rats. Behav. Neurosci. 112:1998;966-978.
44. McNally G.P., Westbrook R.F. Test type influences the expression of lithium chloride-induced hyperalgesia. Pharmacol. Biochem. Behav. 61:1998;385-394.
45. Meller S.T., Dykstra C., Grzybycki D., Murphy S., Gebhart G.F. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology. 33:1994;1471-1478.
46. Meller S.T., Pechman P.S., Gebhart G.F., Maves T.J. Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat. Neuroscience. 50:1992;7-10.
47. Mercadante S., Portenoy R.K. Opioid poorly-responsive cancer pain. Part 1. Clinical considerations. J. Pain Symptom Manage. 21:2001;144-150.
48. Mork A., Geisler A., Hollund P. Effects of lithium on second messenger systems in the brain. Pharmacol. Toxicol. 71:1992;4-17.
49. Nichols M.L., Bian D., Ossipov M.H., Lai J., Porreca F. Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats. J. Pharmacol. Exp. Ther. 275:1995;1339-1345.
50. Nichols M.L., Bian D., Ossipov M.H., Malan T.P., Porreca F. Antiallodynic effects of a CCKB antagonist in rats with nerve ligation injury: role of endogenous enkephalins. Neurosci. Lett. 215:1996;161-164.
51. Ossipov M.H., Lopez Y., Nichols M.L., Bian D., Porreca F. Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci. Lett. 199:1995;83-86.
52. Paletta M.S., Wagner A.R. Development of context-specific tolerance to morphine: support for a dual-process interpretation. Behav. Neurosci. 100:1986;611-623.
53. Paterson S.J., Robson L.E., Kosterlitz H.W. Control by cations of opioid binding in guinea pig brain membranes. Proc. Natl. Acad. Sci. U.S.A. 83:1986;6216-6220.
54. Peterson P.K., Molitor T.W., Chao C.C. The opioid-cytokine connection. J. Neuroimmunol. 83:1998;63-69.
55. Powell K.J., Ma W., Sutak M., Doods H., Quirion R., Jhamandas K. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br. J. Pharmacol. 131:2000;875-884.
56. Reeve A.J., Patel S., Fox A., Walker K., Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur. J. Pain: Ejp. 4:2000;247-257.
57. Ruzicka B.B., Akil H. The interleukin-1beta-mediated regulation of proenkephalin and opioid receptor messenger RNA in primary astrocyte-enriched cultures. Neuroscience. 79:1997;517-524.
58. Shippenberg T.S., Millan M.J., Mucha R.F., Herz A. Involvement of beta-endorphin and mu-opioid receptors in mediating the aversive effect of lithium in the rat. Eur. J. Pharmacol. 154:1988;135-144.
59. Siegel S. Morphine tolerance acquisition as an associative process. J. Exp. Psychol.: Anim. Behav. Process. 3:1977;1-13.
60. Siegel S., Baptista M.A., Kim J.A., McDonald R.V., Weise-Kelly L. Pavlovian psychopharmacology: the associative basis of tolerance. Exp. Clin. Psychopharmacol. 8:2000;276-293.
61. Stanfa L., Dickenson A., Xu X.J., Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol. Sci. 15:1994;65-66.
62. Stengaard-Pedersen K., Schou M. In vitro and in vivo inhibition by lithium of enkephalin binding to opiate receptors in rat brain. Neuropharmacology. 21:1982;817-823.
63. Tiffany S.T., Petrie E.C., Baker T.B., Dahl J.L. Conditioned morphine tolerance in the rat: absence of a compensatory response and cross-tolerance with stress. Behav. Neurosci. 97:1983;335-353.
64. Tilders F.J., DeRijk R.H., Van Dam A.M., Vincent V.A., Schotanus K., Persoons J.H. Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: routes and intermediate signals. Psychoneuroendocrinology. 19:1994;209-232.
65. Tilson H.A., Rech R.H., Stolman S. Hyperalgesia during withdrawal as a means of measuring the degree of dependence in morphine dependent rats. Psychopharmacologia. 28:1973;287-300.
66. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
67. Turrin N.P., Gayle D., Ilyin S.E., Flynn M.C., Langhans W., Schwartz G.J.et al. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res. Bull. 54:2001;443-453.
68. Van Koughnet K., Smirnova O., Hyman S.E., Borsook D. Proenkephalin transgene regulation in the paraventricular nucleus of the hypothalamus by lipopolysaccharide and interleukin-1beta. J. Comp. Neurol. 405:1999;199-215.
69. Vanderah T.W., Ossipov M.H., Lai J., Malan T.P. Jr., Porreca F. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain. 92:2001;5-9.
70. Vanderah T.W., Suenaga N.M., Ossipov M.H., Malan T.P. Jr., Lai J., Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J. Neurosci. 21:2001;279-286.
71. Wajda I.J., Banay-Schwartz M., Manigault I., Lajtha A. Effect of lithium and sodium ions on opiate- and dopamine-receptor binding. Neurochem. Res. 6:1981;321-331.
72. Watkins L.R., Goehler L.E., Relton J., Brewer M.T., Maier S.F. Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Res. 692:1995;244-250.
73. Watkins L.R., McGorry M., Schwartz B., Sisk D., Wiertelak E.P., Maier S.F. Reversal of spinal cord non-opiate analgesia by conditioned anti-analgesia in the rat. Pain. 71:1997;237-247.
74. Watkins L.R., Wiertelak E.P., Furness L.E., Maier S.F. Illness-induced hyperalgesia is mediated by spinal neuropeptides and excitatory amino acids. Brain Res. 664:1994;17-24.
75. Watkins L.R., Wiertelak E.P., Goehler L.E., Mooney-Heiberger K., Martinez J., Furness L.et al. Neurocircuitry of illness-induced hyperalgesia. Brain Res. 639:1994;283-299.
76. Watkins L.R., Wiertelak E.P., Goehler L.E., Smith K.P., Martin D., Maier S.F. Characterization of cytokine-induced hyperalgesia. Brain Res. 654:1994;15-26.
77. Watkins L.R., Wiertelak E.P., McGorry M., Martinez J., Schwartz B., Sisk D.et al. Neurocircuitry of conditioned inhibition of analgesia: effects of amygdala, dorsal raphe, ventral medullary, and spinal cord lesions on antianalgesia in the rat. Behav. Neurosci. 112:1998;360-378.
78. Wiertelak E.P., Furness L.E., Watkins L.R., Maier S.F. Illness-induced hyperalgesia is mediated by a spinal NMDA-nitric oxide cascade. Brain Res. 664:1994;9-16.
79. Wiertelak E.P., Maier S.F., Watkins L.R. Cholecystokinin antianalgesia: safety cues abolish morphine analgesia. Science. 256:1992;830-833.
80. Wiertelak E.P., Roemer B., Maier S.F., Watkins L.R. Comparison of the effects of nucleus tractus solitarius and ventral medial medulla lesions on illness-induced and subcutaneous formalin-induced hyperalgesias. Brain Res. 748:1997;143-150.
81. Wiertelak E.P., Smith K.P., Furness L., Mooney-Heiberger K., Mayr T., Maier S.F.et al. Acute and conditioned hyperalgesic responses to illness. Pain. 56:1994;227-234.
82. Wiertelak E.P., Yang H.Y., Mooney-Heiberger K., Maier S.F., Watkins L.R. The nature of conditioned anti-analgesia: spinal cord opiate and anti-opiate neurochemistry. Brain Res. 634:1994;214-226.
83. Xu X.J., Wiesenfeld-Hallin Z., Hughes J., Horwell D.C., Hokfelt T. CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat. Br. J. Pharmacol. 105:1992;591-596.